- Conditions
- Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors
- Interventions
- Sunitinib (CLOSED TO ENROLLMENT), Trastuzumab and Pertuzumab (CLOSED TO ENROLLMENT), Vemurafenib and Cobimetinib (CLOSED TO ENROLLMENT), Olaparib (CLOSED TO ENROLLMENT), Nivolumab and Ipilimumab (CLOSED TO ENROLLMENT), Abemaciclib (CLOSED TO ENROLLMENT), Talazoparib (CLOSED TO ENROLLMENT), Atezolizumab and Talazoparib (CLOSED TO ENROLLMENT), Tucatinib plus Trastuzumab Subcutaneous (SC) (CLOSED TO ENROLLMENT), Futibatinib, Dabrafenib plus Trametinib, Fam-Trastuzumab Deruxtecan-Nxki (TDxD)
- Drug
- Lead sponsor
- American Society of Clinical Oncology
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 4,200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2028
- U.S. locations
- 174
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Auburn, California + 137 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 193–216
of 6,843
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- TAK-788
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 324 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2026
- U.S. locations
- 36
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Tucson, Arizona + 28 more
- Conditions
- Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD
- Interventions
- Ixo-vec, Aflibercept
- Genetic · Drug
- Lead sponsor
- Adverum Biotechnologies, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 534 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 79
- States / cities
- Mesa, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 65 more
- Conditions
- Depressive Disorder, Major
- Interventions
- LY2216684, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 495 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Beverly Hills, California + 16 more
- Conditions
- Glioblastoma
- Interventions
- Edotecarin, Temozolomide, Carmustine (BCNU), Lomustine (CCNU)
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 118 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2006
- U.S. locations
- 19
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • New Haven, Connecticut + 16 more
- Conditions
- Solid Tumor Cancer, Locally Advanced, Metastatic Solid Tumors, Lung Cancers, Epithelial Tumor, Biliary Tract Cancer (BTC), Urothelial Cancer, Nasopharyngeal Cancers
- Interventions
- AVZO-1418, Combination Agent 1, Combination Agent 2
- Drug
- Lead sponsor
- Avenzo Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 480 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 19
- States / cities
- Gilbert, Arizona • Los Angeles, California • Denver, Colorado + 15 more
- Conditions
- Cardiovascular Disease
- Interventions
- Evacetrapib
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 3
- States / cities
- Miami, Florida • Orlando, Florida • Saint Paul, Minnesota
- Conditions
- Oropharyngeal Carcinoma (OPC)
- Interventions
- CRB-701, capcitabine, Cetuximab (EGFR inhibitor), Docetaxel
- Drug
- Lead sponsor
- Corbus Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 260 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 38
- States / cities
- Huntsville, Alabama • Tucson, Arizona • Duarte, California + 32 more
- Conditions
- Movement Disorders, Muscle Tenderness
- Interventions
- Verbal coaching vs. Constraint based coaching
- Behavioral
- Lead sponsor
- University of Central Florida
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Orlando, Florida
- Conditions
- Respiratory Tract Infections
- Interventions
- Rilematovir, Rilematovir X mg/kg, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 1 Day to 5 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 5
- States / cities
- Orlando, Florida • Jackson, Mississippi • The Bronx, New York + 2 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- metformin, linagliptin, metformin placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 316 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 29
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Chino, California + 26 more
- Conditions
- Organ Donation
- Interventions
- Assisted CEaD Condition, Autonomous CEaD Condition
- Behavioral
- Lead sponsor
- Temple University
- Other
- Eligibility
- 16 Years and older
- Enrollment
- 273 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 9
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Winter Park, Florida + 6 more
- Conditions
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Interventions
- BH-30643, BH-30643 combo therapy with Carboplatin/Pemetrexed
- Drug
- Lead sponsor
- BlossomHill Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 675 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 24
- States / cities
- Phoenix, Arizona • Irvine, California • La Jolla, California + 18 more
- Conditions
- Bipolar Disorder, Depression, Bipolar
- Interventions
- SEROQUEL (quetiapine fumarate) Tablets
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2003
- U.S. locations
- 27
- States / cities
- Birmingham, Alabama • Beverly Hills, California • La Mesa, California + 24 more
- Conditions
- Acute Lymphoblastic Leukemia, Childhood Acute Lymphoblastic Leukemia
- Interventions
- Biospecimen Collection, Compliance Monitoring, Health Promotion and Education, Informational Intervention, Media Intervention, Medical Device Usage and Evaluation, Mercaptopurine, Questionnaire Administration, Telephone-Based Intervention, Training and Education
- Procedure · Behavioral · Other + 1 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 10 Years to 25 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 27
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Oakland, California + 20 more
- Conditions
- Alzheimer Disease
- Interventions
- Cognitive Assessment
- Other
- Lead sponsor
- AdventHealth Translational Research Institute
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 1,423 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Orlando, Florida
- Conditions
- Rhematoid Arthritis
- Interventions
- Tofacitinib with methotrexate, Tofacitinib without methotrexate, Adalimumab with methotrexate
- Drug · Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,152 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 60
- States / cities
- Huntsville, Alabama • Gilbert, Arizona • Covina, California + 47 more
- Conditions
- Postoperative Gastrointestinal Dysfunction
- Interventions
- TAK-954 Placebo, TAK-954
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 209 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 19
- States / cities
- Mobile, Alabama • Los Angeles, California • Orange, California + 14 more
- Conditions
- HIV Infection, Infection, Human Immunodeficiency Virus
- Interventions
- LEXIVA (GW433908), Ritonavir, KALETRA, EPIVIR, Ziagen, Abacavir/Lamivudine, Fosamprenavir
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 866 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2004
- U.S. locations
- 60
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 42 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- Tocilizumab (TCZ), Methotrexate (MTX), Placebo (PBO)
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 718 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 155
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 126 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Dapagliflozin, Placebo, Hydrochlorothiazide
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 154 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 9
- States / cities
- Anaheim, California • Lomita, California • Miami, Florida + 5 more
- Conditions
- Multiple Sclerosis
- Interventions
- Frexalimab, Placebo, MRI contrast-enhancing agents
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 943 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 79
- States / cities
- Homewood, Alabama • Scottsdale, Arizona • Berkeley, California + 68 more
- Conditions
- Hypercholesterolemia, Dyslipidemia
- Interventions
- Placebo, PF-04950615 (RN316)
- Other · Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 29
- States / cities
- Birmingham, Alabama • Garden Grove, California • Long Beach, California + 18 more
- Conditions
- Autism Spectrum Disorder
- Interventions
- ML-004 (IR)/(ER) tablet, ML-004 Placebo
- Drug
- Lead sponsor
- MapLight Therapeutics
- Industry
- Eligibility
- 12 Years to 45 Years
- Enrollment
- 168 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 24
- States / cities
- Dothan, Alabama • Phoenix, Arizona • Glendale, California + 21 more